Barclays’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-10,000
| Closed | -$61.8K | – | 5294 |
|
|
2024
Q2 | $61.8K | Buy |
+10,000
| New | +$55.2K | ﹤0.01% | 4122 |
|
|
2021
Q3 | – | Sell |
-34,400
| Closed | -$544K | – | 4745 |
|
|
2021
Q2 | $544K | Sell |
34,400
-17,000
| -33% | -$231K | ﹤0.01% | 3036 |
|
|
2021
Q1 | $523K | Buy |
+51,400
| New | +$530K | ﹤0.01% | 3154 |
|
|
2020
Q4 | – | Sell |
-68,400
| Closed | -$235K | – | 4873 |
|
|
2020
Q3 | $235K | Sell |
68,400
-83,700
| -55% | -$359K | ﹤0.01% | 3742 |
|
|
2020
Q2 | $725K | Buy |
+152,100
| New | +$607K | ﹤0.01% | 3034 |
|
|
2020
Q1 | – | Sell |
-13,600
| Closed | -$47K | – | 6136 |
|
|
2019
Q4 | $47K | Buy |
13,600
+10,600
| +353% | +$26.7K | ﹤0.01% | 5755 |
|
|
2019
Q3 | $9K | Sell |
3,000
-1,500
| -33% | -$4.67K | ﹤0.01% | 6360 |
|
|
2019
Q2 | $17K | Buy |
4,500
+3,200
| +246% | +$19.3K | ﹤0.01% | 6440 |
|
|
2019
Q1 | $11K | Sell |
1,300
-34,100
| -96% | -$292K | ﹤0.01% | 6529 |
|
|
2018
Q4 | $286K | Buy |
35,400
+4,800
| +16% | +$37.3K | ﹤0.01% | 4322 |
|
|
2018
Q3 | $233K | Buy |
30,600
+8,500
| +38% | +$57.1K | ﹤0.01% | 4882 |
|
|
2018
Q2 | $127K | Buy |
22,100
+12,000
| +119% | +$66.1K | ﹤0.01% | 5079 |
|
|
2018
Q1 | $48K | Sell |
10,100
-30,200
| -75% | -$155K | ﹤0.01% | 5924 |
|
|
2017
Q4 | $198K | Buy |
40,300
+8,600
| +27% | +$41.7K | ﹤0.01% | 4697 |
|
|
2017
Q3 | $166K | Sell |
31,700
-98,200
| -76% | -$503K | ﹤0.01% | 4580 |
|
|
2017
Q2 | $722K | Buy |
129,900
+106,200
| +448% | +$647K | ﹤0.01% | 3175 |
|
|
2017
Q1 | $199K | Buy |
23,700
+14,900
| +169% | +$104K | ﹤0.01% | 4330 |
|
|
2016
Q4 | $56K | Sell |
8,800
-105,600
| -92% | -$549K | ﹤0.01% | 5092 |
|
|
2016
Q3 | $505K | Buy |
114,400
+111,900
| +4,476% | +$447K | ﹤0.01% | 3210 |
|
|
2016
Q2 | $7K | Sell |
2,500
-3,600
| -59% | -$11.2K | ﹤0.01% | 5639 |
|
|
2016
Q1 | $12K | Sell |
6,100
-23,900
| -80% | -$106K | ﹤0.01% | 5407 |
|
|
2015
Q4 | $300K | Buy |
30,000
+1,200
| +4% | +$11.9K | ﹤0.01% | 3591 |
|
|
2015
Q3 | $317K | Buy |
28,800
+2,200
| +8% | +$29.4K | ﹤0.01% | 3756 |
|
|
2015
Q2 | $372K | Buy |
26,600
+500
| +2% | +$5.68K | ﹤0.01% | 3708 |
|
|
2015
Q1 | $235K | Sell |
26,100
-74,400
| -74% | -$770K | ﹤0.01% | 4219 |
|
|
2014
Q4 | $1.21M | Buy |
100,500
+3,700
| +4% | +$40.9K | ﹤0.01% | 3031 |
|
|
2014
Q3 | $871K | Buy |
96,800
+35,200
| +57% | +$431K | ﹤0.01% | 3481 |
|
|
2014
Q2 | $739K | Buy |
61,600
+25,800
| +72% | +$251K | ﹤0.01% | 3617 |
|
|
2014
Q1 | $358K | Buy |
35,800
+7,000
| +24% | +$74.6K | ﹤0.01% | 4231 |
|
|
2013
Q4 | $202K | Sell |
28,800
-13,800
| -32% | -$87.4K | ﹤0.01% | 5002 |
|
|
2013
Q3 | $298K | Buy |
42,600
+37,500
| +735% | +$190K | ﹤0.01% | 4645 |
|
|
2013
Q2 | $8K | Buy |
+5,100
| New | +$8.8K | ﹤0.01% | 7205 |
|
Other funds holding BCRX
RCM
DM
VPM
VCM
TCM
PA
VPC
Barclays's BCRX Position: Q1 2026 in Review
Barclays reduced its BioCryst Pharmaceuticals (BCRX) stake by 82% in Q1 2026, selling an estimated $4.6M and leaving 133,597 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2601.
Barclays first reported a position in BCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.2M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.
- Barclays held 133,597 shares of BioCryst Pharmaceuticals worth $1.27M as of Q1 2026.
- Barclays sold 592,770 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $4.6M.
- BioCryst Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2601 holding.
- Barclays first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's BioCryst Pharmaceuticals position peaked at $7.2M in Q2 2025.
- 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.